{"id":12830,"date":"2025-04-01T16:33:20","date_gmt":"2025-04-01T15:33:20","guid":{"rendered":"https:\/\/resemedicin.se\/reseradet\/?p=12830"},"modified":"2025-04-02T15:26:53","modified_gmt":"2025-04-02T14:26:53","slug":"2025-04-01-nytt-om-chikungunyavacciner","status":"publish","type":"post","link":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-04-01-nytt-om-chikungunyavacciner\/","title":{"rendered":"2025-04-01 Nytt om chikungunyavacciner"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/resemedicin.se\/reseradet\/vaccination\/ixchiq\/\">IXCHIQ\u00ae<\/a>, ett levande f\u00f6rsvagat virusvaccin\u00a0fr\u00e5n\u00a0<a href=\"https:\/\/www.valneva.se\/sv\/general-public\" target=\"_blank\" rel=\"noreferrer noopener\">Valneva<\/a> som finns tillg\u00e4ngligt p\u00e5 den svenska marknaden sedan februari, har efter komplettering med nya s\u00e4kerhetsdata f\u00e5tt godk\u00e4nnande f\u00f6r anv\u00e4ndning fr\u00e5n 12 \u00e5rs \u00e5lder (tidigare fr\u00e5n 18 \u00e5r) &#8221;i enlighet med nationella rekommendationer&#8221;. Se <a href=\"https:\/\/ec.europa.eu\/health\/documents\/community-register\/2025\/20250328165769\/anx_165769_en.pdf\">uppdaterad produktresum\u00e9<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vimkunya-epar-product-information_en.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Vimkunya\u00ae<\/a>\u00a0fr\u00e5n\u00a0<a href=\"https:\/\/www.bavarian-nordic.com\/investor\/news\/news.aspx?news=6941\">Bavarian Nordic<\/a>, \u00e4r ett nytt chikungunyavaccin med renade virusliknande partiklar (VLP) best\u00e5ende av CHIKV-kapsidprotein (C) och h\u00f6ljeproteiner E1 och E2, h\u00e4rledda fr\u00e5n CHIKV Senegal-stam 37997. Vimkunya\u00ae fick den 28 februari marknadsgodk\u00e4nnande inom EU, men finns \u00e4nnu inte tillg\u00e4ngligt p\u00e5 den svenska marknaden. \u00c4ven detta vaccin \u00e4r godk\u00e4nt fr\u00e5n 12 \u00e5rs \u00e5lder.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I avsaknad av svenska nationella rekommendationer har Reser\u00e5det f\u00f6reslagit <a href=\"https:\/\/resemedicin.se\/reseradet\/sjukdomar-och-vacciner\/chikungunya\/#prevention\">indikationer f\u00f6r vaccination f\u00f6r svenska resen\u00e4rer<\/a> som \u00e4r l\u00e4tt modiferade fr\u00e5n de rekommendationer som tagits fram av amerikanska CDC.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IXCHIQ\u00ae, ett levande f\u00f6rsvagat virusvaccin\u00a0fr\u00e5n\u00a0Valneva som finns tillg\u00e4ngligt p\u00e5 den svenska marknaden sedan februari, har efter komplettering med nya s\u00e4kerhetsdata f\u00e5tt godk\u00e4nnande f\u00f6r anv\u00e4ndning fr\u00e5n 12 \u00e5rs \u00e5lder (tidigare fr\u00e5n 18 \u00e5r) &#8221;i enlighet med nationella rekommendationer&#8221;. Se uppdaterad produktresum\u00e9. Vimkunya\u00ae\u00a0fr\u00e5n\u00a0Bavarian Nordic, \u00e4r ett nytt chikungunyavaccin med renade virusliknande partiklar (VLP) best\u00e5ende av CHIKV-kapsidprotein (C) &hellip; <a href=\"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-04-01-nytt-om-chikungunyavacciner\/\" class=\"more-link\">Forts\u00e4tt l\u00e4sa<span class=\"screen-reader-text\"> \u201d2025-04-01 Nytt om chikungunyavacciner\u201d<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"aside","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-12830","post","type-post","status-publish","format-aside","hentry","category-epinytt","post_format-post-format-aside"],"modified_by":"Reser\u00e5det","jetpack_featured_media_url":"","jetpack-related-posts":[{"id":14383,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-06-19-uppdaterade-rekommendationer-for-vaccination-mot-chikungunyafeber\/","url_meta":{"origin":12830,"position":0},"title":"2025-06-19 Uppdaterade rekommendationer f\u00f6r vaccination mot chikungunyafeber","author":"Reser\u00e5det","date":"2025-06-19","format":"aside","excerpt":"Reser\u00e5det har uppdaterat sina rekommendationer r\u00f6rande vaccination mot chikungunyafeber. Avsikten med denna uppdatering \u00e4r b\u00e5de att f\u00f6renkla beslutet om vaccination och att l\u00e5ta dem vila p\u00e5 b\u00e4sta m\u00f6jliga och regelbundet uppdaterade epidemiologiska data. Riskbed\u00f6mningen bakom de nya rekommendationerna baseras nu p\u00e5 ECDC:s kartor i st\u00e4llet f\u00f6r p\u00e5 fall rapporterade till\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/resemedicin.se\/reseradet\/wp-content\/uploads\/2025\/06\/image-9.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":15097,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-10-22-nya-rekommendationer-fran-silf-om-chikungunyavaccination\/","url_meta":{"origin":12830,"position":1},"title":"2025-10-22 Nya rekommendationer fr\u00e5n SILF om chikungunyavaccination","author":"Reser\u00e5det","date":"2025-10-22","format":"aside","excerpt":"Svenska infektionsl\u00e4karf\u00f6reningens programgrupp f\u00f6r vaccinationer har publicerat en v\u00e4gledning f\u00f6r vaccination mot chikungunyafeber. Nedan f\u00f6ljer rekommendationen i sammandrag: Vaccination rekommenderas till Till personer \u226512 \u00e5r som reser till ett omr\u00e5de med p\u00e5g\u00e5ende utbrott kan Vimkunya rekommenderas. I andra hand kan Ixchiq \u00f6verv\u00e4gas, men Ixchiq b\u00f6r undvikas till personer \u226565 \u00e5r.\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":12981,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-05-03-ema-uppmanar-till-forsiktighet-med-ixchiq-till-aldre-sarskilt-multisjuka-individer\/","url_meta":{"origin":12830,"position":2},"title":"2025-05-03 EMA uppmanar till f\u00f6rsiktighet med Ixchiq\u00ae till \u00e4ldre, s\u00e4rskilt multisjuka individer","author":"Reser\u00e5det","date":"2025-05-03","format":"aside","excerpt":"Som vi tidigare rapporterat, har ett antal sv\u00e5ra m\u00f6jliga biverkningar (severe adverse events - SAE) rapporterats efter vaccination med Ixchiq\u00ae, Valnevas levande f\u00f6rsvagade vaccin mot chikungunyafeber. Med anledning av detta har nu \u00e4ven den europeiska l\u00e4kemedelsmyndigheten EMA g\u00e5tt ut med en uppmaning om att tills vidare \"f\u00f6rsiktighet b\u00f6r iakttas vid\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14816,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-08-22-fda-har-tillfalligt-upphavt-licensen-for-ixchiq-i-usa\/","url_meta":{"origin":12830,"position":3},"title":"2025-08-22 Upph\u00e4vd licens f\u00f6r Ixchiq\u00ae i USA","author":"Reser\u00e5det","date":"2025-08-25","format":"aside","excerpt":"Amerikanska l\u00e4kemedelsverket Food and Drug Administration (FDA) har idag upph\u00e4vt licensen i USA f\u00f6r anv\u00e4ndning av Ixchiq\u00ae, Valnevas levande f\u00f6rsvagade vaccin mot chikungunyainfektion. Man skriver p\u00e5 sin hemsida: \"Idag, den 22 augusti 2025, har det amerikanska FDA:s Center for Biologics Evaluation and Research tillf\u00e4lligt upph\u00e4vt licensen f\u00f6r biologiska l\u00e4kemedel f\u00f6r\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":13160,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-05-08-ema-vaccinera-inte-aldre-over-65-ar-med-ixchiq\/","url_meta":{"origin":12830,"position":4},"title":"2025-05-08 EMA: Vaccinera inte \u00e4ldre \u00f6ver 65 \u00e5r med Ixchiq\u00ae","author":"Reser\u00e5det","date":"2025-05-08","format":"aside","excerpt":"OBS! Rekommendationerna nedan g\u00e4ller inte l\u00e4ngre se uppf\u00f6ljande notis i EpiNytt: 2025-07-13 EMA:s granskning av Ixchiq\u00ae klar. Vaccinet kan \u00e5ter ges till \u00e4ldre >65 \u00e5r. Som EpiNytt tidigare rapporterat har s\u00e4kerhetskommitt\u00e9 vid Europeiska L\u00e4kemedelsmyndigheten (EMA) inlett en granskning av chikungunyavaccinet Ixchiq\u00ae efter rapporter om allvarliga biverkningar hos \u00e4ldre personer. M\u00e5nga\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":15207,"url":"https:\/\/resemedicin.se\/reseradet\/epinytt\/2025-11-17-gront-ljus-fran-ema-for-nytt-pertussisvaccin\/","url_meta":{"origin":12830,"position":5},"title":"2025-11-17 Gr\u00f6nt ljus fr\u00e5n EMA f\u00f6r nytt pertussisvaccin","author":"Reser\u00e5det","date":"2025-11-17","format":"aside","excerpt":"Den 13 november 2025 antog europeiska l\u00e4kemedelsmyndighetens (EMA) kommitt\u00e9 f\u00f6r humanl\u00e4kemedel (CHMP) ett positivt yttrande och rekommenderade att vaccinet VacPertagen (BioNet Europe) mot kikhosta, skulle godk\u00e4nnas f\u00f6r f\u00f6rs\u00e4ljning i EU. De aktiva substanserna i VacPertagen \u00e4r tv\u00e5 renade kikhostantigener: rekombinant kikhostetoxin (PTgen) och filament\u00f6st hemagglutinin (FHA). Efter intramuskul\u00e4r administrering av\u2026","rel":"","context":"I \u201dEpiNytt\u201d","block_context":{"text":"EpiNytt","link":"https:\/\/resemedicin.se\/reseradet\/kategori\/epinytt\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/12830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/comments?post=12830"}],"version-history":[{"count":3,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/12830\/revisions"}],"predecessor-version":[{"id":12835,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/posts\/12830\/revisions\/12835"}],"wp:attachment":[{"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/media?parent=12830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/categories?post=12830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/resemedicin.se\/reseradet\/wp-json\/wp\/v2\/tags?post=12830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}